CNS Drugs

, Volume 8, Issue 4, pp 276–284 | Cite as

Histamine H2 Receptor Antagonists in Schizophrenia

Rationale for Use and Therapeutic Potential
  • Stephen I. Deutsch
  • Richard B. Rosse
  • Barbara L. Schwartz
Leading Article

Summary

The serendipitous observation that famotidine, a competitive histamine H2 receptor antagonist, administered as the sole medication to a patient with schizophrenia and coincidental peptic ulcer disease, was associated with a dramatic resolution of positive and negative symptoms, has stimulated the examination of a possible role for histamine in the pathophysiology of schizophrenia. It has been found that the terminal projections of histaminergic neurons originating in the posterior hypothalamus include regions implicated prominently in the pathophysiology of schizophrenia. Elevations of levels of histamine and its principal methylated metabolite in the CSF of patients with schizophrenia have been reported, and selective alterations of histamine receptor subtypes in autopsied brains from patients who had had schizophrenia support the possible existence of pathologically altered histaminergic neurotransmission.

There are also some recent preliminary genetic-epidemiological data suggesting that patients with schizophrenia are more likely to possess an unusual allelic variant of the gene for the H2 receptor. Conceivably, this variant results in altered ‘coupling’ of the receptor, a member of the superfamily of receptors with 7 transmembranous hydrophobic domains, to its guanine triphosphate-binding protein.

Preliminary open-label clinical trials of famotidine as an adjuvant to antipsychotics in patients with schizophrenia have been encouraging and, therefore, support further exploration of H2 receptor antagonists as possible adjunctive medications for schizophrenia.

Keywords

Schizophrenia Histamine Adis International Limited Negative Symptom Famotidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 8: 239–46CrossRefGoogle Scholar
  2. 2.
    Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 196–205PubMedGoogle Scholar
  3. 3.
    Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995; 40(7 Suppl. 2): S60–7PubMedGoogle Scholar
  4. 4.
    Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165: 18–21CrossRefGoogle Scholar
  5. 5.
    Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995; 21: 607–19PubMedGoogle Scholar
  6. 6.
    Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17: 263–87PubMedGoogle Scholar
  7. 7.
    Deutsch SI, Rosse RB, Kendrick KA, et al. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 1993; 16: 518–24PubMedGoogle Scholar
  8. 8.
    Oyewumi LK, Vollick D, Merskey H, et al. Famotidine as an adjunctive treatment of resistant schizophrenia. J Psychiatry Neurosci 1994; 19: 145–50PubMedGoogle Scholar
  9. 9.
    Kaminsky R, Moriarty TM, Bodine J, et al. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1990; 335: 1351–2PubMedCrossRefGoogle Scholar
  10. 10.
    Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48(11): 978–86PubMedCrossRefGoogle Scholar
  11. 11.
    Rosse RB, Kendrick K, Fay-McCarthy M, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996; 19: 341–8PubMedCrossRefGoogle Scholar
  12. 12.
    Rosse RB, Kendrick K, Tsui LC, et al. Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin Neuropharmacology 1995; 18: 369–74CrossRefGoogle Scholar
  13. 13.
    Bonato GW. Manual for the ECDU assessment battery. 2nd rev. ed. Washington, DC: US Department of Health and Human Services, 1970Google Scholar
  14. 14.
    Overall JE, Gorham DE. The brief psychiatrie rating scale. Psychol Rep 1961; 10: 799–812CrossRefGoogle Scholar
  15. 15.
    Andreasen NC, Olsen S. Negative versus positive schizophrenia. Arch Gen Psychiatry 1982; 39: 784–8PubMedCrossRefGoogle Scholar
  16. 16.
    Prell GD, Rosse RB, Deutsch SI. Apparent absence of famotidine-antipsychotic drug interactions [letter]. J Psychiatry Neurosci 1996; 21(1): 61–2PubMedGoogle Scholar
  17. 17.
    Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol 1987; 22 Suppl. 134: 55–60CrossRefGoogle Scholar
  18. 18.
    Sikiric P, Rotkvic I, Mise S, et al. Dopamine agonists prevent duodenal ulcer relapse: a comparative study with famotidine and Cimetidine. Dig Dis Sci 1991; 36: 905–10PubMedCrossRefGoogle Scholar
  19. 19.
    Whiteford HA, Stedman TJ, McGrath JJ, et al. An open-label study of famotidine as treatment for schizophrenia. J Psychiatry Neurosci 1995; 20: 239–40PubMedGoogle Scholar
  20. 20.
    Langtry HD, Grant SM, Goa KL. Famotidine: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 38: 551–90PubMedCrossRefGoogle Scholar
  21. 21.
    Schwartz JC, Arrang JM, Garbarg M, et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1–51PubMedGoogle Scholar
  22. 22.
    Yokoyama H, Iinuma K. Histamine and seizures: implications for the treatment of epilepsy. CNS Drugs 1996; 5(5): 321–30CrossRefGoogle Scholar
  23. 23.
    Pollard H, Schwartz JC. Histamine neuronal pathways and their functions. Trends Neurosci 1987; 10: 86–9CrossRefGoogle Scholar
  24. 24.
    Dietrichs E, Haines DE, Roste GK, et al. Hypothalamocerebellar and cerebellohypothalamic projections — circuits for regulating nonsomatic cerebellar activity? Histol Histopathol 1994; 9: 603–14PubMedGoogle Scholar
  25. 25.
    Martinez-Mir MI, Pollard H, Moreau J, et al. Three histamine receptors (H1, H0, and H3) visualized in the brain of human and non-human primates. Brain Res 1990; 526: 322–7PubMedCrossRefGoogle Scholar
  26. 26.
    Hough LB. Cellular localization and possible functions for brain histamine: recent progress. Prog Neurobiol 1988; 30: 469–505PubMedCrossRefGoogle Scholar
  27. 27.
    Prell GD, Green JP. Histamine as a neuroregulator. Annu Rev Neurosci 1986; 9: 209–54PubMedCrossRefGoogle Scholar
  28. 28.
    Martinez-Mir MI, Pollard H, Moreau J, et al. Loss of striatal histamine H2 receptors in Huntington’s chorea but not in Parkinson’s disease: comparison with animal models. Synapse 1993; 15: 209–20PubMedCrossRefGoogle Scholar
  29. 29.
    Prell GD, Green JP, Kaufmann CA, et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationship to levels of other aminergic transmitters and ratings of behavior. Schizophr Res 1995; 14(2): 93–104PubMedCrossRefGoogle Scholar
  30. 30.
    Nakai T, Kitamura N, Hashimoto T, et al. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 1991; 30: 349–56PubMedCrossRefGoogle Scholar
  31. 31.
    Elkashef AM, Buchanan RW, Gellad F, et al. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am J Psychiatry 1994; 151: 752–5PubMedGoogle Scholar
  32. 32.
    Early TS, Posner MI, Reiman EM, et al. Left striato-pallidal hyperactivity in schizophrenia. II: Phenomenology and thought disorder. Psychiatr Dev 1989; 2: 109–21Google Scholar
  33. 33.
    Early TS, Posner MI, Reiman EM, et al. Hyperactivity of the left striato-pallidal projection. I: Lower level theory. Psychiatr Dev 1989; 2: 85–108Google Scholar
  34. 34.
    Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Reviews 1994; 19: 223–39CrossRefGoogle Scholar
  35. 35.
    Andreasen NC, O’Leary DS, Cizadlo T, et al. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci USA 1996; 93: 9985–90PubMedCrossRefGoogle Scholar
  36. 36.
    Keshavan MS, Tandon R. Sleep abnormalities in schizophrenia: pathophysiological significance. Psychol Med 1993; 23: 831–5PubMedCrossRefGoogle Scholar
  37. 37.
    Horne JA. Human sleep, sleep loss, and behavior: implications for the prefrontal cortex and psychiatric disorder. Br J Psychiatry 1993; 162: 413–9PubMedCrossRefGoogle Scholar
  38. 38.
    Zarcone VP, Benson KL. Sleep and schizophrenia. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 2nd ed. Philadelphia: W.B. Saunders Company, 1994: 914–26Google Scholar
  39. 39.
    Benson KL, Csernansky JG, Zarcone VP. The effect of nitanserin on slow wave sleep deficits and sleep continuity in schizophrenia. Sleep Res 1991; 20: 170Google Scholar
  40. 40.
    Nicholson AN, Pascoe PA, Stone BM. Histaminergic systems and sleep: studies in man with H1 and H2 antagonists. Neuropharmacology 1985; 24: 245–50PubMedCrossRefGoogle Scholar
  41. 41.
    Deutsch SI, Mastropaolo J, Schwartz BL, et al. A ‘glutaminergic hypothesis’ of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12: 1–13PubMedCrossRefGoogle Scholar
  42. 42.
    Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301–8PubMedGoogle Scholar
  43. 43.
    Itoh Y, Oishi R, Nishibori M, et al. Phencyclidine and dynamics of mouse brain histamine. J Pharmacol Exp Ther 1985; 235: 788–92PubMedGoogle Scholar
  44. 44.
    Williams K. Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine. Mol Pharmacol 1994; 46: 531–41PubMedGoogle Scholar
  45. 45.
    Bekkers JM. Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. Science 1993; 261: 104–6PubMedCrossRefGoogle Scholar
  46. 46.
    Orange PR, Heath PR, Wright SR, et al. Allelic variation of the H2 receptor gene. Neuroreport 1996; 7: 1293–6PubMedCrossRefGoogle Scholar
  47. 47.
    Orange PR, Heath PR, Wright SR, et al. Individuals with schizophrenia have an increased incidence of the H2R649G allele for the histamine H2 receptor gene. Mol Psychiatry 1996; 1(6): 466–9PubMedGoogle Scholar
  48. 48.
    Kagevi I, Thorhallsson E, Wahlby L. CSF concentrations of famotidine. Br J Clin Pharmacol 1987; 24: 849–50PubMedCrossRefGoogle Scholar
  49. 49.
    Yoshimoto K, Saima S, Echizen H, et al. Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther 1994; 55: 693–700PubMedCrossRefGoogle Scholar
  50. 50.
    Physicians desk reference. 50th ed. Montvale (NJ): Medical Economics Company, 1996Google Scholar
  51. 51.
    Calcutt CR, Ganellin CR, Griffiths R, et al. Zolantidine (SK&F95282) is a potent selective brain-penetrating histamine H2-receptor antagonist. Br J Pharmacol 1988; 93: 69–78PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Stephen I. Deutsch
    • 1
  • Richard B. Rosse
    • 1
  • Barbara L. Schwartz
    • 1
  1. 1.Psychiatry Service (116A)Department of Veterans Affairs Medical Center and Georgetown University Medical SchoolUSA

Personalised recommendations